This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Firategrast

Mitsubishi Tanabe Pharma Corporation

Drug Names(s): 683699, 4508.T, T-0047, SB-683699

Description: 683699 is a novel oral VLA-4 antagonist (cell adhesion inhibitor [a4B7/a4B1 inhibitor]).

Deal Structure: 683699 is being developed in collaboration with Tanabe Seiyaku Co Ltd.

In October 2007, Mitsubishi Tanabe Pharma Corporation was formed by the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation.

GlaxoSmithKline & Mitsubishi Tanabe
In July 2014, Mitsubishi Tanabe announced that it has terminated its license agreement of T-0047 (Firategrast) for the treatment of multiple sclerosis with GlaxoSmithKline.

Firategrast News

Scrip AbbVie Buys In On Morphic’s Oral Integrin Inhibitors, To Tune Of $100m

Scrip 2012 Scrip 100: Successful trial outcomes – peering into the crystal ball

Scrip UCB and Biogen Idec pull plug on Phase II trial of oral MS drug

Scrip The surge for safety in MS treatment

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug